Stock A001360 SAMSUNG PHARM. CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights SAMSUNG PHARM. Co., LTD.

Equities

A001360

KR7001360007

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 03/06/2024 am IST 		5-day change 1st Jan Change
1,633 KRW +0.49% Intraday chart for SAMSUNG PHARM. Co., LTD. -0.73% -24.92%
2023 NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd. CI
2023 NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 9 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd. CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
SAMSUNG PHARM. Co., LTD. Present Pancreatic Cancer Immunotherapeutic Drug, RIAVAX™, Phase III results at ASCO 2021
CI
An unknown buyer agreed to acquire 38.7% stake in Korea Stem Cell Bank Co., Ltd. from SAMSUNG PHARM. Co., LTD. for KRW 9.9 billion.
CI
SAMSUNG PHARM. Co., LTD. completed the acquisition of an unknown minority stake in True Life Insurance Bank for KRW 12.5 billion.
CI
SAMSUNG PHARM. Co., LTD. acquired 3.1% stake in Enerzent Co., Ltd. for KRW 3 billion.
CI
SAMSUNG PHARM. Co., LTD. acquired 0.16% stake in GemVax Technology Co., Ltd. from Samsung Medicos Co., Ltd. for approximately KRW 220 million.
CI
Korea Stem Cell Bank Co., Ltd. agreed to acquire Samsung Medicos Co., Ltd. from SAMSUNG PHARM. Co., LTD. for KRW 16.3 billion.
CI
Samsung Pharmaceutical Co., Ltd. completed the sale of 17.13% stake in Medizen Humancare Co.,Ltd.
CI
Samsung Pharmaceutical Co., Ltd. agreed to sell 17.13% stake in Medizen Humancare Co.,Ltd. for KRW 2 billion.
CI
Samsung Pharmaceutical Co., Ltd. acquired Shinhwa IM Co., Ltd. for KRW 3.7 billion.
CI
GemVax & Kael Co.,Ltd. completed the acquisition of 18.2% stake in Samsung Pharmaceutical Industry Corporation Limited. from Kim Won Gyu and five related parties.
CI
GemVax & Kael Co.,Ltd. signed a contract to acquire a 18.2% stake in Samsung Pharmaceutical Industry Corporation Limited. from Kim Won Gyu and five related parties for KRW 12 billion.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A001360 Stock
  4. News SAMSUNG PHARM. Co., LTD.
  5. Highlights